


Applicant states in accordance with 37 C.F.R. § 1.821(f) that the content of the enclosed paper sequence listing and computer readable form are the same, and that in accordance with 37 C.F.R. § 1.821(g), the enclosed submission contains no new matter.

Applicant thus submits that the application is now in compliance with the sequence listing requirements, and examination and allowance of this case is earnestly solicited.

Respectfully submitted,

October 9, 2001

LARSON & TAYLOR, PLC
1199 North Fairfax Street
Suite 900
Alexandria, Virginia 22314
(703) 739-4900



B. Aaron Schulman
Registration No. 31,877

09810428 100904
T0600T 8240T860



ATTACHMENT A

Clean Amended Substitute Specification Paragraphs

A clean version of page 9, lines 1-5 is provided.

Figure 2A. Sequence alignment of CNA19 and ACE19. ClustalW with default parameters was used. Shaded amino acid residues were identical and similar residues.

The β -strands and α -helices of CNA19 determined by X-ray crystallography were indicated by dark bars above the corresponding regions of CNA19. β -strands A, B, a part of D, E and H are the ones that form the observed trench and are indicated by *.

Sequences for CNA19 are identified as SEQ ID NOS. 5 to 8, and sequences for ACE19 are identified as SEQ ID NOS. 8 to 12.

A clean version of page 50, lines 12-22 is provided.

3B12VLG-4 (variable light sequence)

GAAGTTGTGATGACCCAACTCCACTCTCCCTGCCTGTCAGTCTTGGCGATCACGC
CTCCATCTCTTGCAGATCTAGTCAGCGCCTTGACACAGTAATGAAAACACCTATTT
ACATTGGTATCTGCAGAAGCCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTT
CCAACCGATTTTCTGGGGTCCCAGACAGGTTTCAGTGGCAGTGGATCAGGGACAGA
TTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTTCTGCT
CTCAAAGTACGCATGTTCTCCACGTTTCGGAGGGGGGACCAGGCTGGAAATAAA
A (SEQ ID NO. 1).

EVVMTQTPLSLPVSLGDHASISCRSSQRLVHSNENTYLHWYLQKPGQSPKLLIYKVS
NRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPTFGGGTRLEIK (SEQ
ID NO. 2)

- Amino acids representing a CDR are underlined

A clean version of page 51, lines 1-12 is provided.

3B12VHB-1 (variable heavy sequence)

CAGGTTTCAGCTGCAGCAGTCTGGAGCTGAGCTGATGAAGCCTGGGGCCTCAGTG
AAGATCTCCTGCAAGGCTGCTGGCTACACATTCAGTCCCTACTGGATAGAGTGGTT
AAAGCAGAGGCCTGGACATGGCCTTGAGTGGATTGGAGAGATTTTACCTGGAAGT
GGAAATATTAACACTACAATGAGAAGTTCAAGGACAAGGCCACATTCAGTCTGATAC
ATCCTCCAACACAGTTTACATGCAAGTCAGCAGCCTGACATCTGAGGACTCTGCCG
TCTATTACTGTGCAAGAGAGGAGGATGGTTACCCGGCCTGGTTTGCTTACTGGGG
CCAAGGGACTCTGGTCACTGTCTCTGCA (SEQ ID NO. 3).

QVQLQQSGAELMKPGASVKISCKAAGYTFSPYWIEWLKQRPGHGLEWIGEILPGSGNI
NYNEKF~~KDKATFTADTSSNTVYMQVSSLTSEDSAVYYCAREEDGYP~~AWFAYWGQGT
LTVSA (SEQ ID NO. 4).

- Amino acids representing a CDR are underlined

A clean version of the heading at page 58, line 1 is provided.

Table 1A. Oligonucleotide primers used in this study (SEQ ID NOS. 13 TO 30, respectively).

ATTACHMENT B

Marked Up Copy of Specification With Amended Paragraphs

A marked up version of page 9, lines 1-5 is provided.

Figure 2A. Sequence alignment of CNA19 and ACE19. ClustalW with default parameters was used. Shaded amino acid residues were identical and similar residues. The β -strands and α -helices of CNA19 determined by X-ray crystallography were indicated by dark bars above the corresponding regions of CNA19. β -strands A, B, a part of D, E and H are the ones that form the observed trench and are indicated by *. Sequences for CNA19 are identified as SEQ ID NOS. 5 to 8, and sequences for ACE19 are identified as SEQ ID NOS. 8 to 12.

A marked up version of page 50, lines 12-22 is provided.

3B12VLG-4 (variable light sequence)

GAAGTTGTGATGACCCAACTCCACTCTCCCTGCCTGTCAGTCTTGGCGATCACGC
CTCCATCTCTTGCAGATCTAGTCAGCGCCTTGACACAGTAATGAAAACACCTATTT
ACATTGGTATCTGCAGAAGCCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTT
CCAACCGATTTTCTGGGGTCCCAGACAGGTTCA GTGGCAGTGGATCAGGGACAGA
TTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTTCTGCT
CTCAAAGTACGCATGTTCTCCACGTTCTGGAGGGGGGACCAGGCTGGAAATAAA
A (SEQ ID NO. 1).

EVVMTQTPLSLPVSLGDHASISCRSSQRLVHSNENTYLHWYLQKPGQSPKLLIYKVS
NRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPTFGGGTRLEIK (SEQ
ID NO. 2)

- Amino acids representing a CDR are underlined

09310423.100901

A marked up version of page 51, lines 1-12 is provided.

3B12VHB-1 (variable heavy sequence)

CAGGTTTCAGCTGCAGCAGTCTGGAGCTGAGCTGATGAAGCCTGGGGCCTCAGTG
AAGATCTCCTGCAAGGCTGCTGGCTACACATTTCAGTCCCTACTGGATAGAGTGGTT
AAAGCAGAGGCCTGGACATGGCCTTGAGTGGATTGGAGAGATTTTACCTGGAAGT
GGAAATATTAACCTACAATGAGAAGTTCAAGGACAAGGCCACATTCACTGCTGATAC
ATCCTCCAACACAGTTTACATGCAAGTCAGCAGCCTGACATCTGAGGACTCTGCCG
TCTATTACTGTGCAAGAGAGGAGGATGGTTACCCGGCCTGGTTTGCTTACTGGGG
CCAAGGGACTCTGGTCACTGTCTCTGCA (SEQ ID NO. 3).

QVQLQQSGAELMKPGASVKISCKAAGYTFSPYWIEWLKQRPGHGLEWIGEILPGSGNI
NYNEKFKDKATFTADTSSNTVYMQVSSLTSEDSAVYYCAREEDGYPAWFAYWGQGT
LTVSA (SEQ ID NO. 4).

- Amino acids representing a CDR are underlined

A marked up version of the heading at page 58, line 1 is provided.

Table 1A. Oligonucleotide primers used in this study (SEQ ID NOS. 13 TO 30, respectively).

106001" 82401960